Clearmind Medicine rises after alcohol addiction drug shows safety in early trial

Clearmind Medicine

14/04/2026 12:44

** Shares of biotech firm Clearmind Medicine CMND.O shares rise 30.83% to $1.87 premarket

** Co says its experimental oral drug CMND-100 is being tested for alcohol use disorder, a condition where people struggle to control heavy drinking

** Says the drug met the main goal of safety in an early-stage clinical trial, with no serious side effects reported

** Adds the treatment was well tolerated, including at the highest dose tested so far

** Says the international study is testing the drug in people with moderate to severe alcohol use disorder and supports further development

** As of last close, stock down ~21% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))